Recurrent Vulvovaginal Candidiasis – Possibility of its Treatment

Czech version

Authors: J. Špaček, BuchtaV. ^{1 2,3}; P. Jílek ³; J. Krejsek ⁴; V. Pidrman ⁵; I. Kalousek ¹; V. Matula ¹; J. Kestřánek ¹; M. Drahošová ⁴; M. Vejsová ³; M. Főrstl ²
Authors‘ workplace: Klinika porodnictví a gynekologie, Fakultní nemocnice a LF UK, Hradec Králové, přednosta doc. MUDr. J. Tošner, CSc. ¹; Ústav klinické mikrobiologie, Fakultní nemocnice a LF UK, Hradec Králové, přednosta doc. RNDr. V. Buchta, CSc. ²; Katedra biologických a lékařských věd, FaF UK, Hradec Králové, vedoucí doc. RNDr. V. Semecký, CSc. ³; Ústav klinické imunologie a alergologie, Fakultní nemocnice a LF UK, Hradec Králové, přednosta prof. RNDr. J. Krejsek, CSc. ⁴; Klinika psychiatrie, Fakultní nemocnice a LF UP, Olomouc, přednosta doc. MUDr. V. Pidrman, Ph. D. ⁵
Published in: Ceska Gynekol 2008; 73(3): 179-184

Overview

Objective:
A review of recurrent vulvovaginal candidiasis and the possibility of its treatment.

Subject:
Original study.

Setting:
Department of Obstetrics and Gynaecology, Medical Faculty Hradec Králové, Charles University, Prague.

Department of Clinical Microbiology, Medical Faculty Hradec Králové, Charles University, Prague.

Department of Biological and Medical Sciences, Faculty of Pharmacy Hradec Králové, Charles University, Prague.

Department of Clinical Imunology and Allergology, Medical Faculty Hradec Králové, Charles University, Prague.

Department of Psychiatry, Medical Faculty Olomouc, Palacky University, Olomouc.

Methods:
Analysis and discussion focused especially on our results and experience in a long time follow-up of patients with confirmed recurrent vulvovaginal candidiasis.

Conclusion:
Owing to the multifactorial character of etiopathogenesis, the management of recurrent vulvovaginal candidiasis would be taken into consideration the complexity of the disease, not only the treatment of individual episodes with antimycotics.

Key words:
yeast, Candida albicans, recurrent vulvovaginal candidiasis, treatment

Sources

1. Buchta, V., Špaček, J. Mikrobiologické nálezy u pacientek s rekurentní vulvovaginální kandidózou ve Fakultní nemocnici Hradec Králové v letech 1995-2002. Čs Gynek, 2004, 69, s. 7-15.

2. Clancy, R., Corrigan, E., Dunkley, M., Eyers, F. Recurrent vulvovaginal candidiasis – allergy or immune deficiency. Int Arch Allergy Immunol, 1999, 118, p. 349-50.

3. Fidel, PL., Sobel, JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev, 1996, 9, p. 335-348.

4. Fidel P., Jr. Immunity in vaginal candidiasis. Curr Opin Infect Dis, 2005, 18, p. 107-111.

5. Giraldo, P., Von Nowaskonski, A., Gomes, FAM., et al. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet Gynecol, 2000, 95, p. 413-416.

6. Hurley, R. Recurrent Candida infection. Clin Obstet Gynecol, 1981, 8, p. 209-213.

7. Jílek, P., Špaček, J., Buchta, V., et al. Systémová imunita u pacientek s rekurentní vulvovaginální kandidózou. Čs Gynek, 2005, 70, s. 453–459.

8. Kestřánek, J. jun., Buchta, V., Špaček, J., et al. Problematika vulvovaginálního dyskomfortu z hlediska mezioborové spolupráce. EMI, 2008, 57, p. 23-27.

9. Li, SP., Lee, S., Domer, J. Alterations in frequency of interleukin-2 (IL-2)-, gamma interferon, or IL-4-secreting splenocytes induced by Candida albicans mannan and/or monophosphoryl lipid A. Infect. Immun, 1998, 66, p. 1392-1399.

10. Nyirjesy, P., Seeney, SM., Grody, MH, et al. Chronic fungal vaginitis: The value of culture. Am J Obstet Gynecol, 1995, 173, p. 820-323.

11. Pidrman, V. Deprese u žen. In: Anders, M., ed. Deprese z různých úhlů pohledu. Praha: Galén, 2006, s. 31-46.

12. Redecha, M., Korbelę, M., Nižňanská, Z., et al. Vulvovaginální kandidóza. Gynekológia pre prax, 2007, 5, s. 117-123.

13. Ringdahl, EN. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician, 2000, 61, p. 3306-3312, 3317.

14. Rodrigues, AG., Mardh, PA., Pina-Vaz, C., et al. Is the lack of concurence of bacterial vaginosis and vaginal candidosis explained by the presence of bacterial amines? Am J Obstet Gynecol, 1999, 181, p. 367-370.

15. Skřivánek, A., Dvořák, V., Hlaváčková, O., et al. Wobenzym in the complex treatment of recurrent vulvovaginal candidiasis. 10th World Congress for Infectious and Immunological Diseases in Obstetrics and Gynaecology, Urology, Dermatology 2007. Proceedings (in press).

16. Sobel, JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci, 1988, 544, p. 547-557.

17. Sobel, JD., Wiesenfeld HC, Martens, M., et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med, 2004, 9, p. 876-883.

18. Špaček, J., Jílek, P., Buchta, V., et al. Současné názory na etiopatogenezi rekurentní vulvovaginální kandidózy. Čs Gynek,1999, 64, s. 114-117.

19. Špaček, J., Buchta, V., Veselský, Z., et al. Interakce kvasinek s hostitelem ve vztahu k urogenitálnímu traktu, vulvovaginální kandidóza, urologické aspekty mykotických onemocnění. Čs Gynek, 2003, 68, s. 432-439.

20. Špaček, J., Jílek, P., Buchta, V., et al. Protihoubová imunita a její mechanismy ve vztahu k vulvovaginální kandidóze. Čs Gynek, 2004, 69, s. 133-140.

21. Špaček, J., Buchta, V. Itraconazole in the treatment of acute and recurrent vaginal candidosis: Comparison of the therapeutic effectiveness and occurrence of relapses in one-day and three-day regimens. Mycoses, 2005, 48, p. 165-171.

22. Špaček, J., Buchta, V., Jílek, P., et al. Assessment of progesterone production in patients with recurrent vulvovaginal candidiasis. 9th World Congress for Infectious and Immunological Diseases in Obstetrics and Gynaecology, Urology and Dermatology, November 19-26, 2005, Maceio, Brazil, Book of Abstratcs (65).

23. Špaček, J., Buchta, V., Jílek, P., et al. What does it mean the diagnosis of recurrent vulvovaginal candidiasis? 9th World Congress for Infectious and Immunological Diseases in Obstetrics and Gynaecology, Urology and Dermatology, November 19-26, 2005, Maceio, Brazil, Book of Abstratcs (62).

24. Špaček, J., Buchta, V., Jílek, P., et al. Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. Europ J of Obst & Gyn and Repr Biol, 2007, 131, p. 198-202.

25. Špaček, J., Jílek, P., Buchta, V., et al. The levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidiasis during attack and remission and in healthy controls. Mycoses, 2005, 48, p. 391-395.

26. Špaček, J., Buchta, V., Jílek, P., et al. Gestagens in the management of recurrent vulvovaginal candidiasis. J Chemother, 2007, 19, Suppl. 3, p.101, 3rd Trends in Medical Mycology. 28-31 October 2007, Turin, Italy

27. Zdolsek, B., Hellberg, D., Fröman, G., et al. Vaginal microbiological flora and sexually transmitted diseases in women with recurrent vulvovaginal candidiasis. Infection, 1995, 23, p. 81-84.